drugset / Trial / NCT03136666

Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.

NCT03136666

Phase 1 Completed 12 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

The objective of the study was to investigate the pharmacokinetics as well as safety and tolerability of a concomitant administration of nifedipine GITS and candesartan tablets under fasting conditions in healthy male subjects.

Timeline

Start
2010-04-19
Primary completion
2010-06-07
Completion
2010-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan cilexetil Unknown 8 mg Oral
Subject Candesartan cilexetil Unknown 16 mg Oral
Subject Candesartan cilexetil Unknown 32 mg Oral
Subject Nifedipine Other / unclassified 30 mg Oral
Subject Nifedipine Other / unclassified 60 mg Oral

Indications

No indication recorded.